Sirolimus-induced interstitial lung disease and resolution after conversion to everolimus

Mammalian target of rapamycin inhibitors (mTORi) are used to treat a variety of malignancies and have an established role in organ transplantation. Interstitial lung disease (ILD) is one of the complications of mTORi and is believed to be a class effect. More cases of ILD have been reported with sir...

Descripción completa

Detalles Bibliográficos
Autores principales: Alkhunaizi, Ahmed M., Al-Khouzaie, Thamer H., Alsagheir, Ahmed I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287142/
https://www.ncbi.nlm.nih.gov/pubmed/32551222
http://dx.doi.org/10.1016/j.rmcr.2020.101109
Descripción
Sumario:Mammalian target of rapamycin inhibitors (mTORi) are used to treat a variety of malignancies and have an established role in organ transplantation. Interstitial lung disease (ILD) is one of the complications of mTORi and is believed to be a class effect. More cases of ILD have been reported with sirolimus than with everolimus in the literature, possibly due to earlier introduction and wider use of sirolimus. We report the case of a kidney transplant recipient who developed ILD secondary to sirolimus and improved rapidly after switching to everolimus.

Ejemplares similares